Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
Founded in 2019, OphthaFund is an early-stage investment organization based in the United States. The firm focuses on the ophthalmology and life sciences sectors, connecting investors with innovative ideas. It conducts extensive research into intellectual property and market analysis to support startups.
OphthaFund invests in early-stage companies within the ophthalmology and biotechnology sectors, targeting Seed, Series A, and Series B stages. The firm emphasizes a meticulous approach to due diligence, seeking ventures with strong market potential and clear pathways to commercialization.
OphthaFund has backed several companies, including MCAL Therapeutics (Seed investment), Encore Pharmaceuticals (Seed investment, later acquired by Novartis), ForwardVue Pharma (Seed investment), ONL Therapeutics (Seed investment), Premark Pharma (Seed investment), and Allysta Pharmaceuticals (Seed, Series A, and Series B investments).
Submit your pitch through their website's contact form for consideration.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.